Double‐blind therapeutic trial in Angelman syndrome using betaine and folic acid
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Angelman syndrome (AS) is caused by reduced or absent expression of the maternally inherited ubiquitin protein ligase 3A gene (UBE3A), which maps to chromosome 15q11–q13. UBE3A is subject to genomic imprinting in neurons in most regions of the brain. Expression of UBE3A from the maternal chromosome is essential to prevent AS, because the paternally inherited gene is not expressed, probably mediated by antisense UBE3A RNA. We hypothesized that increasing methylation might reduce expression of the antisense UBE3A RNA, thereby increasing UBE3A expression from the paternal gene and ameliorating the clinical phenotype. We conducted a trial using two dietary supplements, betaine and folic acid to promote global levels of methylation and attempt to activate the paternally inherited UBE3A gene. We performed a number of investigations at regular intervals including general clinical and developmental evaluations, biochemical determinations on blood and urine, and electroencephalographic studies. We report herein the data on 48 children with AS who were enrolled in a double‐blind placebo‐controlled protocol using betaine and folic acid for 1 year. There were no statistically significant changes between treated and untreated children; however, in a small subset of patients we observed some positive trends. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jiang, Y.-H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G., Sweatt, J. D., & Beaudet, A. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80596-6 · Cited by 852 · cited 2×
“One carries a null mutation of the maternal UBE3A gene and is associated with motor dysfunction, inducible seizures, and long-term potentiation (LTP) deficits [Jiang et al., 1998b].”
BackgroundMethodSelf-citationDindot, S. V., Antalffy, B. A., Bhattacharjee, M. B., & Beaudet, A. L. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm288 · Cited by 418
Self-citationA mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A
Jiang, Y., Sahoo, T., Michaelis, R. C., Bercovich, D., Bressler, J., Kashork, C. D., Liu, Q., Shaffer, L. G., Schroer, R. J., Stockton, D. W., et al. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30297 · Cited by 159
Self-citation
Cited by
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
Huang, H.-S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Lee, H.-M., Chen, X., et al. (2012) · Nature · doi:10.1038/nature10726 · Cited by 387
“, raising the possibility that Angelman syndrome could be treated by activating this silenced allele to restore functional UBE3A protei”
BackgroundAngelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes
Mabb, A. M., Judson, M. C., Zylka, M. J., & Philpot, B. D. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.04.001 · Cited by 263
“Moreover, efforts to unsilence the intact paternal UBE3A allele with dietary supplements that increase DNA methylation have failed [26].”
BackgroundMargolis, S. S., Sell, G. L., Zbinden, M. A., & Bird, L. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0361-y · Cited by 165
Self-citationAngelman syndrome: advancing the research frontier of neurodevelopmental disorders
Philpot, B. D., Thompson, C. E., Franco, L., & Williams, C. A. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-010-9066-z · Cited by 17
Metadata
- Authors
- Peters, S. U., Bird, L. M., Kimonis, V., Glaze, D. G., Shinawi, L. M., Bichell, T. J., Barbieri‐Welge, R., Nespeca, M., Anselm, I., Waisbren, S., Sanborn, E., Sun, Q., O'Brien, W. E., Beaudet, A. L., & Bacino, C. A.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2010-07-20
- Volume
- 152A
- Issue
- 8
- Pages
- 1994-2001
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W2115869719
- Cited by
- 44
- References
- 3
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐blind therapeutic trial in Angelman syndrome using betaine and folic acid. https://app.cochat.ai/papers/10.1002/ajmg.a.33509
- The paper
- Peters, S. U., Bird, L. M., Kimonis, V., Glaze, D. G., Shinawi, L. M., Bichell, T. J., Barbieri‐Welge, R., Nespeca, M., Anselm, I., Waisbren, S., Sanborn, E., Sun, Q., O'Brien, W. E., Beaudet, A. L., & Bacino, C. A. (2010). Double‐blind therapeutic trial in Angelman syndrome using betaine and folic acid. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.33509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.